Show simple item record

dc.contributor.authorMiddleton, MR
dc.contributor.authorSteven, NM
dc.contributor.authorEvans, TJ
dc.contributor.authorInfante, JR
dc.contributor.authorSznol, M
dc.contributor.authorHamid, O
dc.contributor.authorShoushtari, AN
dc.contributor.authorAnthoney, A
dc.contributor.authorGupta, Avinash
dc.contributor.authorWoodcock, VK
dc.contributor.authorAbdulla, S
dc.contributor.authorCorrie, P
dc.date.accessioned2020-03-27T09:28:04Z
dc.date.available2020-03-27T09:28:04Z
dc.date.issued2020en
dc.identifier.citationMiddleton MR, Steven NM, Evans TJ, Infante JR, Sznol M, Hamid O, et al. Relationship between clinical efficacy and AEs of tebentafusp, a novel bispecific TCR-anti-CD3, in patients with advanced melanoma. Journal of Translational Medicine. 2020;18en
dc.identifier.urihttp://hdl.handle.net/10541/622852
dc.language.isoenen
dc.titleRelationship between clinical efficacy and AEs of tebentafusp, a novel bispecific TCR-anti-CD3, in patients with advanced melanomaen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Oncology, Medical Sciences Division, University of Oxford, Oxford,en
dc.identifier.journalJournal of Translational Medicineen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record